Get the Stockscreener App
1.77
5.35%
-0.10
After Hours:
1.75
-0.02
-1.13%
Nrx Pharmaceuticals Inc stock is traded at $1.77, with a volume of 707.11K.
It is down -5.35% in the last 24 hours and up +5.36% over the past month.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.
See More
Previous Close:
$1.87
Open:
$1.88
24h Volume:
707.11K
Relative Volume:
0.77
Market Cap:
$56.41M
Revenue:
-
Net Income/Loss:
$-30.15M
P/E Ratio:
-0.4425
EPS:
-4
Net Cash Flow:
$-21.66M
1W Performance:
-8.29%
1M Performance:
+5.36%
6M Performance:
-35.64%
1Y Performance:
-17.29%
1-Day Range:
$1.74
$1.88
1-Week Range:
$1.74
$1.93
52-Week Range:
$1.58
$3.84
Nrx Pharmaceuticals Inc Stock (NRXP) Company Profile
Name
Nrx Pharmaceuticals Inc
Sector
Industry
Phone
484-254-6134
Address
1201 ORANGE STREET, WILMINGTON
Compare NRXP vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NRXP
Nrx Pharmaceuticals Inc
|
1.77 | 59.60M | 0 | -30.15M | -21.66M | -4.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Nrx Pharmaceuticals Inc Stock (NRXP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-08-25 | Initiated | H.C. Wainwright | Buy |
| Apr-02-25 | Initiated | BTIG Research | Buy |
Nrx Pharmaceuticals Inc Stock (NRXP) Latest News
HC Wainwright Has Positive Estimate for NRXP FY2026 Earnings - MarketBeat
Targets Report: Is NRx Pharmaceuticals Inc backed by strong institutional buying2025 Trading Recap & Verified Entry Point Signals - baoquankhu1.vn
What are NRx Pharmaceuticals Inc. Equity Warrant’s growth leversQuarterly Portfolio Summary & Low Risk Entry Point Guides - mfd.ru
H.C. Wainwright raises NRx Pharmaceuticals stock price target to $45 - Investing.com Nigeria
Q3 EPS Forecast for NRx Pharmaceuticals Decreased by Analyst - MarketBeat
NRXP Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
NRx Pharmaceuticals (NASDAQ:NRXP) Stock Rating Upgraded by Zacks Research - MarketBeat
NRx Pharmaceuticals (NASDAQ:NRXP) Price Target Raised to $45.00 - MarketBeat
NRx Pharmaceuticals appoints Joshua Brown as chief medical officer - Investing.com
NRx Pharmaceuticals (NASDAQ: NRXP) Appoints Prof. Joshua C. Brown As Chief Medical Innovation Officer - Digital Journal
NRx Pharmaceuticals (NASDAQ: NRXP) Completes FDA Type C Meeting for NRX-100 NDA Pathway - Digital Journal
NRx Pharmaceuticals Appoints Prof. Joshua Brown MD, PhD, as Chief Medical Innovation Officer - Investing News Network
NRx Pharmaceuticals appoints Joshua Brown as chief medical officer By Investing.com - Investing.com Canada
Harvard brain-stimulation leader joins NRx to target PTSD, depression - Stock Titan
What is the dividend yield of NRx Pharmaceuticals IncMarket Risk Analysis & Fast Moving Stock Trade Plans - baoquankhu1.vn
NRx Builds Momentum From FDA Progress To Strategic Expansion - National Today
NRx Builds Momentum From FDA Progress To Strategic Expansion | Corporate - EQS News
NRXP Technical Analysis & Stock Price Forecast - Intellectia AI
EQS-News: Benzinga: NRx Builds Momentum From FDA Progress To Strategic Expansion - FinanzNachrichten.de
NRXP Should I Buy - Intellectia AI
NRXPW Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
NRx Reports FDA Guidance on NRX-100 Approval Path - MyChesCo
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
Bipolar Depression Clinical Trial Pipeline Appears Robust With 8+ Key Pharma Companies Actively Working in the Domain | DelveInsight - StreetInsider
Trade Report: Can NRx Pharmaceuticals Inc stock outperform in a bear market2025 Trading Recap & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
Weekly Buzz: NRXP Sets The Path For NRX-100's NDA; IRON Gets FDA's CRL; TOVX Licenses SYN-020 - finanzen.ch
Moving Averages: What is the earnings history of Guidewire Software Inc2025 Technical Overview & Expert Approved Momentum Ideas - baoquankhu1.vn
Ideas Watch: Is NRx Pharmaceuticals Inc backed by strong institutional buyingQuarterly Profit Review & Risk Adjusted Buy/Sell Alerts - baoquankhu1.vn
NRx and FDA Meeting Advances New Drug Application for NRX-100 - Intellectia AI
NRx Pharmaceuticals’ (NRXP) “Buy” Rating Reaffirmed at BTIG Research - Defense World
BTIG Research Reaffirms "Buy" Rating for NRx Pharmaceuticals (NASDAQ:NRXP) - MarketBeat
NRx Pharmaceuticals (Nasdaq:NRXP) Announces Path to New Drug Application with Real World Data and Broader Proposed Indication for NRX-100 (ketamine) Following Type C FDA Meeting - The Globe and Mail
NRx Pharmaceuticals Announces Path to New Drug Application - citybiz
FDA Meeting Indicates Path to New Drug Application with Real World Data and Broader Indication of NRX-100 (Ketamine) for Suicidal Depression: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) - StreetInsider
FinancialContentFDA Meeting Indicates Path to New Drug Application with Real World Data and Broader Indication of NRX-100 (Ketamine) for Suicidal Depression: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) - FinancialContent
NRx Pharmaceuticals Establishes $20 Million ATM Stock Program - TipRanks
[8-K] NRX Pharmaceuticals, Inc. Reports Material Event | NRXP SEC FilingForm 8-K - Stock Titan
NRx Pharmaceuticals Charts Path To NDA For NRX-100 Following FDA Guidance - Nasdaq
FDA Meeting Indicates a pivotal development that could redefine the treatment landscape for suicidal depression via NRx Pharmaceuticals: $NRXP - PRLog
NRx Pharmaceuticals (NASDAQ:NRXP) Given "Buy" Rating at D. Boral Capital - MarketBeat
Nrx Pharmaceuticals announces path to new drug application with real world data - marketscreener.com
NRx Pharmaceuticals Announces Path to New Drug Application with Real World Data and Broader Proposed Indication for NRX-100 Following Type C FDA Meeting - Investing News Network
NRx Pharmaceuticals (Nasdaq:NRXP) Announces Path to New Drug Application With Real World Data and Broader Proposed Indication for NRX-100 (Ketamine) Following Type C FDA Meeting - 富途牛牛
What is NRx Pharmaceuticals Inc.’s book value per share2025 Price Targets & Low Risk High Reward Trade Ideas - mfd.ru
CEO Change: What is the Moat Score of IGC Pharma IncProduct Launch & Weekly High Momentum Picks - baoquankhu1.vn
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Sees Significant Decrease in Short Interest - MarketBeat
Aug Gainers: Can NRx Pharmaceuticals Inc reach resistance levels soon2025 Institutional Moves & Daily Market Momentum Tracking - baoquankhu1.vn
How NRx Pharmaceuticals Inc. stock benefits from global expansionMarket Growth Review & Daily Volume Surge Trade Alerts - mfd.ru
What’s the beta of NRx Pharmaceuticals Inc. stockTrade Exit Summary & High Conviction Buy Zone Alerts - mfd.ru
Is NRx Pharmaceuticals Inc. stock a buy before product launchesWeekly Loss Report & Technical Confirmation Alerts - mfd.ru
What’s the MACD signal for NRx Pharmaceuticals Inc.July 2025 Highlights & Entry and Exit Point Strategies - mfd.ru
Nrx Pharmaceuticals Inc Stock (NRXP) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.69%
0.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):